PMID- 38425650
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240302
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 15
DP  - 2024
TI  - Identification of claudin-2 as a promising biomarker for early diagnosis of 
      pre-diabetes.
PG  - 1370708
LID - 10.3389/fphar.2024.1370708 [doi]
LID - 1370708
AB  - Introduction: Pre-diabetes, a high-risk metabolic state, is situated between 
      normal glucose homeostasis and diabetes. Early identification of pre-diabetes 
      offers opportunities for intervention and diabetes reversal, highlighting the 
      crucial need to investigate reliable biomarkers for this condition. Methods: We 
      conducted an in-depth bioinformatics analysis of clinical samples from 
      non-diabetic (ND), impaired glucose tolerance (IGT), and type 2 diabetes mellitus 
      (T2DM) categories within the GSE164416 dataset. Thereafter the HFD and STZ 
      treated mice were used for validation. Results: This analysis identified several 
      codifferentially expressed genes (Co-DEGs) for IGT and T2DM, including CFB, TSHR, 
      VNN2, APOC1, CLDN2, SLPI, LCN2, CXCL17, FAIM2, and REG3A. Validation of these 
      genes and the determination of ROC curves were performed using the GSE76895 
      dataset. Thereafter, CLDN2 was selected for further verification. Gene expression 
      analysis and immunofluorescence analysis revealed a significant upregulation of 
      CLDN2 expression in the pancreas islets of mice in the high-fat diet and T2DM 
      groups compared to the control group. Similarly, serum level of CLDN2 in patients 
      with IGT and T2DM were significantly higher than those in the healthy group. 
      Discussion: These results suggest that CLDN2 can serve as a novel biomarker for 
      pre-diabetes, providing a new direction for future research in the prevention of 
      type 2 diabetes.
CI  - Copyright (c) 2024 Songtao, Fangyu, Jie and Li.
FAU - Songtao, Yang
AU  - Songtao Y
AD  - Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Fangyu, Li
AU  - Fangyu L
AD  - Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Jie, Cao
AU  - Jie C
AD  - Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Li, Yuan
AU  - Li Y
AD  - Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
LA  - eng
PT  - Journal Article
DEP - 20240215
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10902111
OTO - NOTNLM
OT  - biomarker
OT  - claudin-2
OT  - diabetes
OT  - impaired glucose tolerance
OT  - pre diabetes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/03/01 06:43
MHDA- 2024/03/01 06:44
PMCR- 2024/02/15
CRDT- 2024/03/01 03:50
PHST- 2024/01/15 00:00 [received]
PHST- 2024/02/05 00:00 [accepted]
PHST- 2024/03/01 06:44 [medline]
PHST- 2024/03/01 06:43 [pubmed]
PHST- 2024/03/01 03:50 [entrez]
PHST- 2024/02/15 00:00 [pmc-release]
AID - 1370708 [pii]
AID - 10.3389/fphar.2024.1370708 [doi]
PST - epublish
SO  - Front Pharmacol. 2024 Feb 15;15:1370708. doi: 10.3389/fphar.2024.1370708. 
      eCollection 2024.